eBook: The new oncology drug development imperatives

Adapting oncology drug development to a post-COVID world.

Oncology is a uniquely complex therapeutic area, and as the coronavirus pandemic has accelerated the adoption of new innovations, such as decentralized clinical trials (DCTs) and real-world evidence (RWE). There will be no going back.

In this new eBook, Parexel experts and one insightful patient explore the many ways COVID-19 has changed drug development — and what new imperatives oncology drug developers can adopt to speed life-changing therapies to patients in need.

• Incorporating novel surrogate endpoints
• Leveraging external / synthetic control arms
• Patient insights for oncology trial design
• Benefits of demonstrating value earlier

Please complete the short form below to download the eBook.

We are always available for a conversation.


Communication Preference

Communication Preference